Valley Fever Market

 Market Overview:

TThe 7 major valley fever markets reached a value of USD 717.46 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,046.45 Million by 2035, exhibiting a growth rate (CAGR) of 3.49% during 2025-2035.

The valley fever market has been comprehensively analyzed in IMARC's new report titled "Valley Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Valley fever, also called coccidioidomycosis, is a type of fungal infection caused by the coccidioides fungus, which grows in arid soil and dirt. Some people may have no indications at all, while others may develop flu-like symptoms, such as fever, cough, headache, fatigue, etc. However, many individuals may experience more worsening indications, including chest pain, shortness of breath, night sweats, headaches, muscle aches, joint pain, etc. In rare cases, the infection can spread to other parts of the body, such as the skin, bones, and brain, causing severe symptoms like skin lesions, meningitis, or even death. The diagnosis of valley fever requires a combination of the patient's travel history, clinical features, and a physical examination. A blood test can also be utilized to determine the presence of antibodies or antigens in the body. The healthcare provider may perform numerous imaging studies, such as chest X-rays, computerized tomography scans, etc., that provide lung pictures to visualize a potentially serious complication. In severe cases, a biopsy of the affected site is recommended for a detailed investigation and confirmation of the illness.

The increasing incidence of exposure to fungus spores that thrive in soil disruptions caused by human or animal activity, including construction sites and farming operations, is primarily driving the valley fever market. In addition to this, the rising prevalence of various associated risk factors, such as advancing age, weakened immune system, occupational hazards, etc., is also bolstering the market growth. Furthermore, the widespread adoption of antifungal medications, including fluconazole and itraconazole, for treating the ailment is acting as another significant growth-inducing factor. These pharmacological agents work by inhibiting the synthesis of a vital part of the fungal cell membrane that reduces the fungus's ability to replicate and prevents disease progression in patients. Additionally, numerous key players are making extensive investments in R&D activities to introduce immunomodulatory therapies, such as interferon-gamma or granulocyte-macrophage colony-stimulating factor (GM-CSF), which can help to boost the immune system's response to the infection. This, in turn, is further creating a positive outlook for the market. Moreover, the ongoing development of a two-dose human vaccine for the condition, since it encourages an immune response against the fungus and provides long-term protection from the infection, is expected to drive the valley fever market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the valley fever market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for valley fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the valley fever market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the valley fever market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the valley fever market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current valley fever marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the valley fever market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the valley fever market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the valley fever market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of valley fever across the seven major markets?
• What is the number of incident cases (2019-2035) of valley fever by age across the seven major markets?
• What is the number of incident cases (2019-2035) of valley fever by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with valley fever across the seven major markets?
• What is the size of the valley fever patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of valley fever?
• What will be the growth rate of patients across the seven major markets?
   

Valley Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for valley fever drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the valley fever market?
• What are the key regulatory events related to the valley fever market?
• What is the structure of clinical trial landscape by status related to the valley fever market?
• What is the structure of clinical trial landscape by phase related to the valley fever market?
• What is the structure of clinical trial landscape by route of administration related to the valley fever market?